Literature DB >> 12102255

Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension.

T F Andoh1, R J Johnson, T Lam, W M Bennett.   

Abstract

Cyclosporine use is highly associated with the development of salt-sensitive hypertension. We hypothesized that subtle renal injury induced by cyclosporine could lead to salt sensitivity. Cyclosporine nephropathy was induced by treatment for 4 weeks with cyclosporine (15 mg/kg/day) on a low sodium (0.05%) diet, followed by stopping cyclosporine and placement on a high sodium (4%) diet for 4 additional weeks. Control groups included a group treated with cyclosporine (15 mg/kg/day) on a normal salt diet in which nephropathy does not develop, and a vehicle-treated group. A fourth group received half-dose of cyclosporine (8 mg/kg/day) on a low sodium diet, which results in mild nephropathy. Biopsies were obtained at the end of the cyclosporine administration (4 week) and at sacrifice (8 week), and blood pressure and renal function were measured. Rats treated with cyclosporine for 4 weeks on a low sodium diet developed classic features of tubulointerstitial disease and arteriolopathy; these changes were absent in the cyclosporine/normal salt group and in the vehicle group. At 4 weeks, all groups were switched to a high salt diet; only the rats with nephropathy developed hypertension. The degree of hypertension correlated closely with the degree of tubulointerstitial injury (r=0.85) and with the severity of the arteriolopathy (r=0.9) (p<0.0.1). Importantly, renal function (creatinine clearance) was normal in all groups at 8 weeks, documenting that the hypertension could not be attributed to cyclosporine-mediated alterations in glomerular filtration rate (GFR). One mechanism by which cyclosporine induces hypertension is the induction of subtle renal microvascular and tubulointerstitial disease. This mechanism is not dependent on GFR and may persist even after the cyclosporine is discontinued.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12102255     DOI: 10.1046/j.1600-6135.ajt10305.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  Association of kidney function and albuminuria with prevalent and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Minxuan Huang; Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Brad C Astor; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2014-08-21       Impact factor: 8.860

Review 2.  Pathogenesis of essential hypertension: historical paradigms and modern insights.

Authors:  Richard J Johnson; Dan I Feig; Takahiko Nakagawa; L Gabriela Sanchez-Lozada; Bernardo Rodriguez-Iturbe
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

3.  Renal histopathological findings in relation to ambulatory blood pressure in chronic kidney disease patients.

Authors:  Kotaro Haruhara; Nobuo Tsuboi; Kentaro Koike; Akira Fukui; Yoichi Miyazaki; Tetsuya Kawamura; Makoto Ogura; Takashi Yokoo
Journal:  Hypertens Res       Date:  2014-09-18       Impact factor: 3.872

Review 4.  Renal infiltration of immunocompetent cells: cause and effect of sodium-sensitive hypertension.

Authors:  Bernardo Rodriguez-Iturbe
Journal:  Clin Exp Nephrol       Date:  2010-02-19       Impact factor: 2.801

5.  Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.

Authors:  Miguel L Graciano; Akira Nishiyama; Keith Jackson; Dale M Seth; Rudy M Ortiz; Minolfa C Prieto-Carrasquero; Hiroyuki Kobori; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2007-11-07

6.  Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis.

Authors:  Bryan Kestenbaum; Kyle D Rudser; Ian H de Boer; Carmen A Peralta; Linda F Fried; Michael G Shlipak; Walter Palmas; Catherine Stehman-Breen; David S Siscovick
Journal:  Ann Intern Med       Date:  2008-04-01       Impact factor: 25.391

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.